It is important to understand how low grade tumors recur and progress to malignant lesions since this dramatically shortens patient survival. Here, we evaluated the concept that malignant progression and poor prognosis of low grade astrocytic tumors are TP53 dependent through clonal expansion of mutated cells. TP53 status was established in primary and recurrent tumors from 36 patients with WHO grade II astrocytic tumors and two tumor types were found. Tumors from 14 patients (39%; type 1) had TP53 mutated cells, and 92% of these recurred with 57% progressing to malignancy. The evolution of TP53 mutated cells before and after progression was examined using a clonal analysis procedure in yeast. Malignant progression was accompanied by an increased percentage of mutant TP53 (red) yeast colonies resulting from monoclonal expansion of cells with mutated TP53. The presence of TP53 mutations in WHO grade II astrocytic tumors was associated with malignant progression (P=0.034, w 2 test) and shorter progression-free survival (PFS; 47.6+9.6 months for TP53-mutated tumors vs 67.8+8.2 months for TP53-wild type tumors, P50.05, log-rank test). Tumors from 22 patients (61%; type 2) were without TP53 mutations, and 64% of these recurred without a change in TP53 status, although 41% progressed to malignancy. This suggests that TP53 mutation is not an initiating or progression event in the majority of low grade astrocytic tumors. Our study also indicates that irradiation for WHO grade II astrocytic tumors might be associated with poor outcome (P50.0001) and this was independent of TP53 status. These ®ndings have important implications in the clinical management of patients with low grade astocytoma and provide new support to the clonal evolution model for tumor progression.
Introduction
Low grade astrocytic tumors are second in frequency to glioblastoma among all gliomas, and third among all primary brain tumors (CBTRUS, 1997) . With the exception of pilocytic variants, astrocytomas almost invariably become malignant and cannot be totally resected because they are diusely in®ltrative to normal brain. Greater than 50% of astrocytic tumors progress to a higher grade within a median time of 15 months. This malignant progression is responsible for the majority of patient mortality despite modern surgical technology and adjunct therapies (Chen et al., 1995) . Overall 5-and 10-year patient survival rates are approximately 30 ± 45% and 20 ± 30%, respectively (reviewed in Salcman, 1995) . However, for unknown reasons some tumors do not demonstrate malignant progression, allowing patients to achieve long-term survival. This suggests the existence of dierent astrocytoma subgroups. At present the clinical and histological features of astrocytic tumors display heterogeneity and do not allow one to predict malignant recurrence, highlighting the need for novel prognostic factors (Salcman, 1995) .
As with other tumors, malignant progression of astrocytic tumors is believed to result from the clonal expansion of cells acquiring increasing numbers of genetic alterations (Nowell, 1976) . Mutations in the TP53 gene are known to occur early in astrocytoma progression. Since p53 appears to play a role in monitoring genomic integrity, loss of its activity would accelerate malignant progression as genetically unstable cells would acquire new genetic defects at an increased rate. Initial studies in patients with low grade astrocytoma showing malignant recurrence have sustained this model. Hayashi et al. (1991) examined the recurrent tumors of four low grade gliomas with wild type TP53 and found that three contained mutant TP53 alleles. Sidransky et al. (1992) demonstrated that two low grade astrocytomas containing 8 and 21% mutant TP53 cells, respectively, recurred as glioblastoma consisting of 95 ± 98% of mutant TP53 cells. These small tumor numbers did not allow the determination of whether this was a general phenomenon, nor the evaluation of whether dierent subclassses of low grade astrocytoma exist: non-recurrent versus recurrent and with or without TP53 mutation.
Here, we expanded on these preliminary ®ndings by examining larger tumor numbers and using a new technique, clonal analysis in yeast. Moreover, we also investigated whether knowledge of TP53 status carries prognostic value for low grade astrocytic tumors. The yeast p53 functional assay allows both the examination of p53 transcriptional function and the estimation of the relative ratios of mutant (detected as red yeast) versus wild type (white yeast) forms of p53 transcripts in tissues (see Materials and methods and Figure 1 ). This technique can detect as little as 10% of cells with mutated TP53 alleles in a tissue and does not detect polymorphisms. Using this assay, we chose to analyse TP53 gene status in WHO grade II astrocytomas and their recurrent tumors in 36 patients (representing 69 , 1997) . Genetically A and OA are also similar (Maintz et al., 1997) , and there is no signi®cant dierence in outcome between diuse AII and OAII (Salcman, 1995) . The prognosis of OA is considered to be similar to either A or O, although no large survival studies of OA are available at present. For these reasons, we considered it important to interrelate clinical behavior and TP53 status in both A and mixed OA.`Pure' oligodendroglioma were not included in this study (Maintz et al., 1997; Reifenberger et al., 1994) . Our data suggest that astrocytic tumors with TP53 mutations have higher recurrence rates than those with wild type TP53 and that these recurrences are always accompanied by clonal expansion of TP53 mutant cells as predicted by the clonal expansion model for tumor progression (Nowell, 1976) . We also found that the occurrence of TP53 mutations in WHO grade II astrocytic tumors is associated with an unfavorable prognosis.
Results

Patient outcome
Of the 36 patients with low grade astrocytic tumors analysed, 27 patients showed recurrence during the observation period (12 ± 186 months, median 72 months) (Tables 1 and 2 ). The 5-and 10-year survival rates were 62.6 and 30.7%, respectively. Twenty patients died of tumor progression during the observation period. Median time to progression (TTP) and overall survival (OS) periods were 48 and 74 months, respectively. Twelve of 14 patients were disease free or without evidence of tumor regrowth at the end point of the observation with a median survival of 94.5 months (range 31 ± 186 months). For one patient (case 26) survival information was not available (see Materials and methods). Statistical analyses revealed no signi®cant dierence in the survival of patients with OA from those with A (log-rank test; PFS: P=0.5499, OS: P=0.4654, w 2 test; P=0.5620) consistent with previous observations (Salcman, 1995) . There was a trend toward increased survival for patients receiving radical vs palliative surgery (Tables  3 and 4) .
TP53 status in primary and recurrent tumors
The 36 patients were classi®ed in two categories according to TP53 gene status of their tumors (Table 1) . Type 1 groups 14 patients (39%) who all had tumors with TP53 mutations (cases 1 ± 14). Thirteen of 14 patients (cases 1 ± 13) with TP53 mutations showed tumor recurrence (93%) and one (case 14) did not (7%). Six primary WHO grade II tumors recurred as WHO grade IV (cases 1 ± 6), 3 as grade III (cases 7 ± 9), two as grade II (cases 10, 11) and for two the recurrence was not operated (cases 12, 13). For 14 of 24 patients with recurrence both primary and recurrent tumors were available for analysis. TP53 status in the primary tumor was always predictive of TP53 status in the recurrent tumor. There were no cases where TP53 mutation was absent in the primary tumor but present in the recurrence. When TP53 was mutated in the initial tumor, the yeast assay always showed an increased percentage of red yeast colonies in the recurrent tumor, except in one case (case nine) which revealed a reduced percentage in the recurrent tumor (WHO grade II) but a higher percentage in the re-recurrent tumor (WHO grade IV). Furthermore, recurrent tumors always contained the same TP53 mutation as found in the respective initial tumors. One patient (case three) had a constitutively mutated TP53 allele at codon 283H. This allele acquired a second mutation 267L in the tumor while the second allele was altered by a mutation at codon 258D. There was no evidence for dierent cell populations in the tumor which would have acquired TP53 mutations independently. Tumors were always monoclonal for TP53 mutation. Type 2 groups 22 patients (61%) who did not have TP53 mutations in their primary or recurrent tumors (cases 15 ± 36). Fourteen of these patients showed tumor recurrence (64%) and eight (36%) did not. Three primary WHO grade II tumors recurred as WHO grade IV (cases 15 ± 17), six as grade III (cases 18 ± 23), two as grade II (cases 24, 25) and for three the recurrence was not operated (cases 26 ± 28). These results show that WHO grade II tumors recur by both TP53 mutation-dependent and independent pathways. Recurrence occurs at high frequency (93%; 13 of 14 patients) in TP53 mutated tumors by monoclonal expansion of TP53 mutated cells.
Relationship between TP53 status and outcome
On univariate analysis, the presence of TP53 mutation was signi®cantly associated with shorter PFS (Figure 2a ; Table 3 ). Mean progression free survival (PFS) for the patients with mutant TP53 was 47.6+5.0 months while that for wild type TP53 was 71.4+9.9 months (P50.05). Multivariate analysis showed a strong trend toward a shorter PFS of the patients with TP53 mutations (P=0.057). Overall survival (OS) for the patients with mutant TP53 was relatively shorter compared to that with wild type TP53 but this dierence was not signi®cant (log-rank test: P=0.13, Cox multivariate: P=0.163; Figure 2b ; Table 3 ). TP53 mutation was also strongly associated with malignant progression when examined for 30 cases whose histological data of recurrent tumors are available (w 2 test: P=0.0344, Figure 2 Relationship between TP53 gene mutation and outcome. Actual survival curves for 32 A/OA patients with or without TP53 mutations, including alive (!) and deceased (.) patients at the end of the observation periods. (a) TP53 mutation was signi®cantly associated with shorter PFS (P50.05). (b) Outcome for patients with wild type TP53 was relatively better than those with mutation but the dierence did not reach statistical signi®cance (P=0.13). PFS=progression free survival; OS=overall survival Figure 3) . We show for the ®rst time that the presence of TP53 mutations in A/OA II is associated with malignant transformation and shorter PFS (P50.05). Malignant progression was accompanied by increased percentages of red yeast colonies, which shows that the ratio of cells with mutated TP53 increases with progression. This indicates that clonal expansion is due to TP53 mutation per se or another alteration that occurs in cells once they have acquired mutated TP53. These ®ndings support and extend preliminary results on two AII patients where TP53 mutated cells found in the recurrent tumors were already present in primary low grade tumors (Sidransky et al., 1992) . We further show that the progression of low grade astrocytoma occurs by monoclonal expansion of TP53 mutated cells. This could not be established in the former study due to the TP53 mutant speci®c hybridization technique utilized (Sidransky et al., 1992) . This contrasts with polyclonal evolution of TP53 ®eld mutations found in esophageal cancer (Waridel et al., 1997) . For 12 of 13 patients, the tumors showed only a single type of mutant TP53 allele, presumably because the other allele was still wild type or had been lost. We did not perform loss of heterozygosity analysis since constitutive material was not available for most patients. In one patient (case 3 in Table 2 ) evidence for three dierent TP53 alleles was found in the tumors. This was explained by the fact that one of these was a constitutively mutated allele (283H) which subsequently acquired a second mutation (267L). The second allele was inactivated by a 258D mutation (detailed analysis of this patient will be reported elsewhere). These data suggest that in low grade A/OA, a mutation in TP53 confers an immediate growth advantage to the cells. Alternatively, if the eect of mutating TP53 only promotes acquisition of new growth-promoting defects due to genomic instability then, these should occur faster than the appearance of novel TP53 mutations elsewhere in the tumor.
A trend to poor outcome had been previously observed in patients with p53 immunopositive astrocytic tumors without reaching statistical signi®cance (al Sarraj and Bridges, 1995; Chozick et al., 1994; Iuzzolino et al., 1994; Kyritsis et al., 1995) , and others have found no dierence (Kraus et al., 1994) . These studies are limited by the inaccuracy of immunohistochemistry in the determination of p53 status (Hall and Lane, 1994) . SSCP and sequencing were used in two other studies focusing only on astrocytic tumors with recurrence. The ®rst one analysing 15 patients found that the patients with TP53 mutations had post recurrence survival (PRS) times nearly twice as long as those without mutations (van Meyel et al., 1994) . We did not con®rm this observation. In our study patients with TP53 mutations had a PRS of 24.7+7.0 (mean+s.e.m.) months versus 27.0+8.8 months with WT TP53 (log-rank test: P=0.603). The second study observed a shorter time interval until progression (TTP) in patients with TP53 mutated tumors, although this study did not reach statistical signi®cance (Watanabe et al., 1997) . Our study now con®rms and extends this preliminary observation.
Secondly, our results suggest that the majority of primary low grade astrocytic tumors (61%; 22 of 36 patients) do not have detectable TP53 mutated cells (Table 1) . Over half of these tumors recurred (14 of 22) within a median time of 33 months and none of them showed acquisition of a TP53 mutation at recurrence. The other eight tumors did not recur in a median follow-up time of 85 months. Although these data need to be sustained by more patients, based on this preliminary evidence we can divide low grade astrocytic tumors without TP53 mutations in two groups: those that will recur (type 2a in Figure 3 ) and those that will not (type 2b). Therefore, TP53 mutation is not an initiating event in the tumorigenesis of type 2 low grade astrocytic tumors. In type 1 tumors we do not exclude that TP53 mutation initiated the tumorigenic process since the percentage of red colonies is an underestimate of TP53 mutated cells in the tumor sections analysed due to the presence of normal brain cells. Careful microdissection cannot alleviate this problem because astrocytic tumor cells diusely in®ltrate normal tissue, hence the`diuse' appellation of astrocytoma grade II. These results help clarify the issue of whether TP53 mutation is`the' initiation event of astrocytoma tumorigenesis or is an early progression event, an issue which has been controversial for some time (reviewed in Fulci et al., 1998) . These data also show that only 48% (13 of 27) of secondary glioblastoma result from a malignant transformation pathway involving clonal expansion of cells with TP53 mutation. The p53 pathway could be altered by alternative means in type 2 tumors, but we did not ®nd evidence for mdm2 overexpression by immunohistochemistry (not shown). Finally, our study suggests that irradiation of low grade astrocytic tumors may be associated with poor outcome. The ecacy of radiotherapy for low grade gliomas is still controversial. Some retrospective studies have reported a bene®t of postoperative radiotherapy in terms of prolonged survival when compared with no radiotherapy, while some did not (reviewed in Vecht, 1993) . To solve this question, a large prospective randomized trial is ongoing (EORTC 22845). Despite small numbers, our results revealed that the patients who were randomly assigned for radiation therapy had much shorter PFS and OS. Based on this intriguing, but preliminary observation, the possibility of radiation promoting glioma progression needs to be carefully evaluated.
In conclusion, our study suggests that the presence of TP53 mutation in low grade astrocytic tumors is associated with malignant progression and poor outcome. This is likely due to a selective growth advantage bestowed upon cells with mutated TP53 leading to clonal expansion and malignant progression as predicted in the clonal evolution model for tumor progression (Nowell, 1976) .
Materials and methods
Patients and tumors
For this study we selected patients with primary low grade (WHO grade II) astrocytic tumors for which frozen tumor tissue was available to allow TP53 status and clonal evolution analysis using a yeast assay (see below). The tumor bank of the Department of Neurosurgery, CHUV, Lausanne, was screened for tumors frozen during the 1983 ± 1995 period. A total of 60 primary tumors were retrieved; 40 astrocytomas and 20 mixed oligoastrocytomas. After an initial survey for the amount of frozen tissue available for RNA extraction, 20 cases had to be excluded. Histological diagnosis of the remaining tumors was re-examined independently by three neuropathologists (RC Janzer, KV Meagher, OD Wistler) who were not informed of TP53 status nor clinical outcome, using WHO criteria (Kleihues et al., 1993) . Four additional cases were dismissed due to disagreement upon diagnosis. The clinical characteristics of the remaining 36 patients are summarized in Tables 1 and 2 . Nine patients were female and 27 were male. Twenty-seven patients had one of more tumor recurrences (cases 1 ± 16 and 15 ± 28). In nine patients the tumor did not recur (cases 14 and 26 ± 36). Nine tumors progressed from WHO grade II to IV and nine from II to III. Four tumors recurred as grade II and the grade of recurrence could not be determined for ®ve other tumors since no operation was performed. Karnofsky Performance Status (KPS) were 90 ± 100% in all the patients. Among these 36 patients eight were randomly assigned for radiation therapy of 5400 cGy for their initial tumors (cases 3, 5, 12, 16, 18, 21, 24 and 27) . For the remaining 28 patients the initial tumors were not irradiated. Recurrent tumors were irradiated in 12 cases and treated with chemotherapy (CCNU or PCV) in seven cases. Patients outcome was accessed by reviewing the medical records or by telephone interviews. The primary tumors included 28 astrocytomas WHO grade II (AII) and eight mixed oligoastrocytomas WHO grade II (OAII). In our study, mixed OA had between 30 and 50% oligodendroglioma cells. During the follow-up periods (12 ± 186 months, median 72 months), 27 patients (75%) showed recurrence that was con®rmed by biopsy and/or neuroimaging studies (Tables 1 and 2 ). The histological diagnosis of one biopsied sample of a regrown tumor (case 25) could not be determined because it consisted of gliotic tissue although the presence of tumor cells was not excluded. In ®ve cases, a second surgery was not performed (cases 12, 13, 26, 27 and 28) . Three A (cases 6, 11, and 20) recurred as OA or oligodendroglioma (O), and one OA (case 21) recurred as O.
TP53 mutation analysis using a p53 functional assay in yeast Frozen material was available for 31 of 36 primary tumors, 16 of 24 recurrent tumors and three of six re-recurrent tumors. Frozen tissues were sectioned for histological analysis to eliminate zones containing normal brain tissue by microdissection. Subsequent sections were used to prepare poly (A) + RNA for TP53 cDNA synthesis by reverse transcription with primer RT1. Exons 2 ± 11 were subsequently ampli®ed by PCR with Pfu DNA polymerase using P3 and P4 primers and were cloned into an expression vector by transformation and homologous recombination in yeast as previously described (Flaman et al., 1995; Waridel et al., 1997) . In this assay, yeast express tumor-derived WT or mutant TP53 cDNA. The yeast are de®cient for adenosine synthesis but contain an exogenous construct with an ADE2 gene that can be transcriptionally activated by WT but not mutant p53. Yeast expressing WT p53 are white and those expressing mutant p53 are red (Figure 1) . In contrast to SSCP this assay detects only functionally inactivating mutants of p53. In one patient (case 3), mRNA was also extracted from leukocytes to analyse constitutional TP53 status for this patient. Plasmid DNA was rescued from 4 ± 20 independent yeast colonies for each tumor as described previously and TP53 cDNA sequence was established using an ABI PRISM automated sequencer. Fourteen of 36 patients with one or more tumors with TP53 mutations were classi®ed as`TP53 mutated' (type 1 in Table 1 ), the remainder were considered`TP53 mutation-free' (type 2).
Statistical analyses
The eect of individual parameters on outcome of the patients was tested using a log-rank test on Kaplan-Meier actuarial survival curves. The progression-free-survival (PFS) was de®ned as the time period in months from the initial to the second operation or to the point when regrowth was con®rmed by imaging study. The overall survival (OS) time was determined at the time interval from the initial operation to death or the date of the end point of the observation (September 1, 1998). One patient (case 10) who died perioperatively was excluded from the survival study. Another patient (case 26) whose clinical record was only available until 22 months after surgery, the time when recurrence was con®rmed by imaging study, was excluded from the survival study. The Cox proportional hazard model was applied for multivariate analyses to determine the contribution of individual factors to PFS and OS. We also examined the relationship between parameters including TP53 status, age, surgical extent, and with or without postsurgical radiation using w 2 test.
